Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Completes Warrant Exercise, Pulling in Additional $17.6M in Proceeds

NEW YORK (GenomeWeb News) – Certain investors have exercised warrants to purchase 12.1 million shares of Vermillion's common stock, providing the company $17.6 million in proceeds, Vermillion said late Thursday.

Oracle Investment Management, Jack Schuler, Matthew Strobeck, and other investors exercised the warrants, which were issued in conjunction with an equity financing deal that closed in May. The total investment from the deal is about $30.9 million before transaction costs, Vermillion said.

Proceeds will be directed at increasing test sales, improving reimbursements for the company's OVA1 ovarian cancer diagnostic test, expanding commercial opportunities in the US and new markets, and advancing additional next-generation ovarian cancer diagnostic tests.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.